N-[(1S)-2-[(3-Methylbutyl)amino]-2-oxo-1-(phenylmethyl)ethyl]-2-pyrazinecarboxamide is an impurity of Bortezomib (B675700) which is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway.
